PointState Capital’s AstraZeneca AZN Stock Holding History

PointState Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-33,675	Closed	-$4.45M	–	51
2022 Q2	$4.45M	Buy	+33,675	New	+$4.42M	0.11%	45
2021 Q4	–	Sell	-410,950	Closed	-$48.4M	–	123
2021 Q3	$49.4M	Buy	410,950 +76,755	+23%	+$8.93M	0.82%	32
2021 Q2	$40M	Sell	334,195 -100,412	-23%	-$11M	0.69%	48
2021 Q1	$43.2M	Buy	434,607 +367,107	+544%	+$36.9M	0.85%	44
2020 Q4	$6.75M	Buy	+67,500	New	+$7.15M	0.13%	84
2018 Q2	–	Sell	-143,650	Closed	-$10M	–	162
2018 Q1	$10M	Buy	+143,650	New	+$9.95M	0.11%	99

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

PointState Capital's AZN Position: Q3 2022 in Review

PointState Capital sold out of AstraZeneca (AZN) in Q3 2022, closing a stake of 33,675 shares — an estimated $4.45M sold.

PointState Capital first reported a position in AZN in Q1 2018 and held it in 6 quarters. The position peaked at $49.4M in Q3 2021. 965 funds tracked by Wall St. Rank hold AZN as of Q3 2022.

PointState Capital reported no remaining AstraZeneca position as of Q3 2022 after selling out during the quarter.
PointState Capital sold 33,675 AstraZeneca shares in Q3 2022, an estimated $4.45M.
PointState Capital first reported a position in AstraZeneca in Q1 2018 and held it in 6 quarters.
PointState Capital's AstraZeneca position peaked at $49.4M in Q3 2021.
965 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2022.

Based on PointState Capital's 13F filing for Q3 2022, filed 10 Nov 2022.